Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-targeted mRNA vaccine for refractory EBV-associated malignancies
ChiCTR2200065962Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of EBV-targeted mRNA vaccine in nasopharyngeal carcinoma (NPC), Epstein-Barr virus-associated gastric cancer (EBVaGC), natural killer/T-cell lymphoma (NKTL) and 1 more (5 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-limiting toxicities (DLTs) and incidence, Safety (dose escalation stage) and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
EBV-targeted mRNA vaccine
03
Conditions
nasopharyngeal carcinoma (NPC)Epstein-Barr virus-associated gastric cancer (EBVaGC)natural killer/T-cell lymphoma (NKTL)Epstein-Barr virus-associated cancer
Beyond the preview
Go deeper on ChiCTR2200065962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065962.